Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$92.96 Million
zł386.54 Million PLN
Market Cap Rank
#20981 Global
#115 in Poland
Share Price
zł141.80
Change (1 day)
+1.87%
52-Week Range
zł136.20 - zł196.80
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.

Scope Fluidics SA - Asset Resilience Ratio

Latest as of September 2025: 16.51%

Scope Fluidics SA (SCP) has an Asset Resilience Ratio of 16.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
zł23.40 Million
Cash + Short-term Investments
Total Assets
zł141.67 Million
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2023–2024)

This chart shows how Scope Fluidics SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Scope Fluidics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents zł0.00 0%
Short-term Investments zł23.40 Million 16.51%
Total Liquid Assets zł23.40 Million 16.51%

Asset Resilience Insights

  • Good Liquidity Position: Scope Fluidics SA maintains a healthy 16.51% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Scope Fluidics SA Industry Peers by Asset Resilience Ratio

Compare Scope Fluidics SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF
Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710
Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860
Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980
Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820
Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710
Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for Scope Fluidics SA (2023–2024)

The table below shows the annual Asset Resilience Ratio data for Scope Fluidics SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 12.84% zł22.19 Million zł172.87 Million -7.76pp
2023-12-31 20.60% zł20.90 Million zł101.49 Million --
pp = percentage points